This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why Glaxo (GSK) Steadily Stays Ahead of Its Industry
by Zacks Equity Research
Shares of Glaxo (GSK) surpass the industry this year. Here are some reasons for the same.
Forget Pfizer, Add These Big Drugmakers to Your Portfolio
by Kinjel Shah
Buy these three large drug companies instead of Pfizer (PFE) as the stock is down this year.
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health
Here's Why Merck (MRK) is Outperforming Its Industry Of Late
by Zacks Equity Research
Merck's shares are up 11.9% this year so far on strong performance and positive regulatory updates related to its PD-1 inhibitor, Keytruda.
Pfizer (PFE) Down 11.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 Cancer Treatment Stocks to Enrich Your Portfolio
by Tirthankar Chakraborty
Investments in cancer therapies are expected to rise almost $250 billion by 2023, from $150 billion in 2018. Thus, companies that are coming up with innovative methods to cure this malaise are great investment choices.
Pharma Stock Roundup: ABBV's Rinvoq Gets FDA Nod, BAYRY to Sell Animal Health Unit
by Kinjel Shah
FDA approves AbbVie's (ABBV) upadacitinib to be marketed as Rinvoq. Bayer (BAYRY) is set to divest its Animal Health unit to Elanco for $7.6 billion in a cash-and-stock deal.
Pfizer's Xtandi Label Expansion Filing Gets Priority Review
by Zacks Equity Research
If data from ARCHES study is approved to be included in the label of Pfizer's (PFE) Xtandi, it can treat a broader prostate cancer patient population.
Glaxo Submits First Regulatory Application for Daprodustat
by Zacks Equity Research
Glaxo (GSK) seeks approval for its anemia candidate, daprodustat, in Japan. Moreover, once every two months administration of cabotegravir and rilpivirine shows non-inferiority to once a month administration in HIV patients in a clinical study.
Teva Launches Generic Version of Mylan's EpiPen for KIds
by Zacks Equity Research
Teva (TEVA) launches generic version of Mylan's (MYL) popular EpiPen Jr allergy treatment at a price of $300 for a pack of two.
AstraZeneca's Imfinzi Fails in Stage IV Lung Cancer Study
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi fails to improve overall survival in a study for previously treated stage IV non-small cell lung cancer (NSCLC) patients.
Bayer Inks $7.6B Deal to Divest Animal Health Unit to Elanco
by Zacks Equity Research
Bayer (BAYRY) inks deal with Elanco to divest its animal health business for $7.6 billion.
Bayer Sells Animal Health Division to Elanco: Now What?
by Mitchell Moore
On Tuesday, Bayer (BAYRY) announced the sale of its animal-health division to American competitor Elanco (ELAN), for a net price of $7.6 billion. The deal is expected to close in mid-2020 after regulatory approval.
Exelixis (EXEL) Stock Up 15.2% YTD on Strong Cabometyx Sales
by Zacks Equity Research
Exelixis (EXEL) continues to fortify its footing in the kidney cancer market on strong Cabometyx performance.
Sarepta Stock Falls as FDA Denies Approval to Golodirsen
by Zacks Equity Research
The CRL to golodirsen NDA comes as a surprise for Sarepta (SRPT) and investors as no issues were raised by the FDA during the review period that could have lead to non-approval of the candidate.
Solid Biosciences Surges on DMD Gene Therapy Study Amendments
by Zacks Equity Research
Solid Biosciences (SLDB) amends its phase I/II gene therapy study protocol to expedite the development of its lead candidate, SGT-001, as potential treatment for DMD.
Pharma Stock Roundup: Pipeline/Regulatory Updates From JNJ, LLY, AZN, RHHBY
by Kinjel Shah
FDA approves Roche's (RHHBY) tumor-agnostic medicine, Rozlytrek, J&J's Sirturo for young TB patients.
Merck's Cancer Immunotherapy Keytruda Continues to Aid Growth
by Zacks Equity Research
Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.
Vaccinex (VCNX) Attains Full Enrollment in Lung Cancer Study
by Zacks Equity Research
Vaccinex (VCNX) completes enrollment in a phase Ib/II study of its pipeline candidate pepinemab in combination with Bavencio for treating advanced non-small cell lung cancer.
Deciphera's GIST Drug Succeeds in Pivotal Study, Stock Up 80%
by Zacks Equity Research
Deciphera's (DCPH) pipeline candidate, ripretinib, improves progression free survival in a pivotal study evaluating it in previously treated, advanced gastrointestinal stromal tumors.
Amgen Wins Enbrel U.S. Patent Litigation Against Novartis
by Zacks Equity Research
Despite lower demand hurting volumes of Enbrel, it remains the largest drug for Amgen (AMGN). A district court decision prevents Novartis from launching Erelzi, its biosimilar version of Enbrel.
Pharma Stock Roundup: AGN, NVO Earnings, EU Nod to SNY & ABBV Drugs for New Patients
by Kinjel Shah
Allergan (AGN) and Novo Nordisk (NVO) report Q2 results. AbbVie's (ABBV) Maviret and Sanofi's (SNY) Dupixent receive approval for new patient population in Europe.
Sarepta (SRPT) Q2 Loss Widens Y/Y, Golodirsen Nears Approval
by Zacks Equity Research
Sarepta (SRPT) reports wider year-over-year loss. However, revenues increase year over year. The company plans expansion of gene therapy program into other indications including multiple sclerosis.
Aerie (AERI) Beats on Q2 Earnings & Sales, Lowers Guidance
by Zacks Equity Research
Aerie (AERI) lowers its annual sales guidance and reports a narrower loss in Q2.
Conatus (CNAT) Beats on Q2 Earnings, Stops Emricasan Studies
by Zacks Equity Research
Conatus' (CNAT) earnings and revenues surpass estimates in the second quarter. However, the company stalls the development of its lead candidate emricasan.